|
US2014323577A1
|
|
Methods for reducing the risk of conversion to clinically definite multiple sclerosis
|
|
US2014197013A1
|
|
Apparatus and method for loading and unloading containers
|
|
WO2012162339A1
|
|
Use of teriflunomide for reducing occurrence of relapses requiring healthcare resources
|
|
TW201249429A
|
|
Use of teriflunomide for treating cognitive impairment
|
|
SG192116A1
|
|
Medical product package
|
|
WO2012061062A1
|
|
Use of teriflunomide for improving motor function
|
|
WO2012061060A1
|
|
Use of teriflunomide for treating brain atrophy
|
|
TW201212911A
|
|
Use of teriflunomide for treating Multiple Sclerosis
|
|
EP2600861A1
|
|
Use of teriflunomide for treating multiple sclerosis
|
|
TW201201795A
|
|
Use of teriflunomide for maintaining fatigue level of a patient having multiple sclerosis
|
|
WO2011150017A1
|
|
Use of terilfunomide for maintaining fatigue level of a patient having multiple sclerosis
|
|
TW201208674A
|
|
Use of teriflunomide for treating brain atrophy
|
|
WO2012050640A1
|
|
Apparatus and method for loading and unloading containers
|
|
EP2470269A1
|
|
Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis
|
|
MX2012003023A
|
|
Synthesis of (4-fluoro-3-piperidin-4-yl-benzyl)-carbamic acid tert-butyl ester and intermediates thereof.
|
|
WO2011019680A1
|
|
Process for preparing 4-methyl-3-thienylamine hydrochloride
|
|
TW201111350A
|
|
Process for preparing 2-arylamino or heteroarylamino substituted benzimidazole compounds
|
|
TW201113278A
|
|
Process for preparing 2-chloro-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine useful as a sodium/proton exchanger type 3 inhibitor
|
|
BRPI0917519A2
|
|
Process for preparing a 7-chloro-n, n, 5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4h-pyridazine [4,5-b] indol-1-polymorph acetamide
|
|
WO2009002955A1
|
|
Process for the preparation of (2r)-2-[4-(7-bromo-2-quinolyloxy)phenoxy]propanoic acid
|
